Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Annals of Surgical Oncology|September 10, 2017
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase InhibitorVictor Manuel Villalobos, Francis Hall, Antonio Jimeno, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Haematologica|June 26, 2025
Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trialLaura E Hogan, Teena Bhatla, Xinxin Xu, et al.
Investigational New Drugs|January 20, 2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancerQing Zhou, Daniel Gustafson, Sujatha Nallapareddy, et al.
Blood Advances|June 3, 2026
Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemiaFranco Locatelli, Musa Karakukcu, Van Huynh, et al.
Pediatric Blood & Cancer|October 10, 2022
Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemiaMichael J Burke, David S Ziegler, Francisco Bautista, et al.
Haematologica|May 7, 2016
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphomaConnie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Annals of Surgical Oncology|September 10, 2017
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase InhibitorVictor Manuel Villalobos, Francis Hall, Antonio Jimeno, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Haematologica|June 26, 2025
Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trialLaura E Hogan, Teena Bhatla, Xinxin Xu, et al.
Investigational New Drugs|January 20, 2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancerQing Zhou, Daniel Gustafson, Sujatha Nallapareddy, et al.
Blood Advances|June 3, 2026
Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemiaFranco Locatelli, Musa Karakukcu, Van Huynh, et al.
Pediatric Blood & Cancer|October 10, 2022
Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemiaMichael J Burke, David S Ziegler, Francisco Bautista, et al.
Haematologica|May 7, 2016
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphomaConnie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
Pageof 12